Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Millennium Pharmaceuticals has reported that a drug combination including Velcade has shown significant activity in previously untreated multiple myeloma patients. If the drug is approved in this setting, it is likely to mount a strong challenge to existing first-line regimens.
Published By Datamonitor
|
19 Sep 2007 |
|
CommentWire
|
Novartis's Tasigna has been approved in the US for use in chronic myeloid leukemia patients that are resistant or intolerant to standard first-line therapies, including the company's blockbuster drug Gleevec. Second-line approval of Tasigna means that Novartis can continue to dominate the chronic myeloid leukemia market across multiple lines of therapy.
Published By Datamonitor
|
30 Oct 2007 |
|
CommentWire
|
A lower once-daily starting dose of Bristol-Myers Squibb's Sprycel is now recommended for patients with chronic-phase chronic myeloid leukemia resistant or intolerant to prior therapy including Gleevec. Further efficacy data in a greater number of patients have also been incorporated. These changes may enable further uptake of the drug in this increasingly competitive niche market.
Published By Datamonitor
|
13 Nov 2007 |
|
CommentWire
|
Interim Phase III results suggest Millennium Pharmaceuticals' Velcade can achieve a four-fold increase in complete remission rates when combined with a commonly-used treatment regimen for first-line multiple myeloma. Together with other ongoing first-line trials, final results will undoubtedly broaden Velcade's applicability and potentially create a new standard of care in the front-line setting.
Published By Datamonitor
|
10 Dec 2007 |
|
CommentWire
|
The clinical hold on a Phase III trial of Vion Pharmaceuticals' Cloretazine in acute myelogenous leukemia has been lifted by the FDA after the company agreed to trial modifications. Vion now hopes that the new trial design will not reduce the efficacy of its lead anticancer pipeline drug.
Published By Datamonitor
|
10 Jan 2008 |
|
CommentWire
|
Pharmion has submitted a Marketing Authorization Application with the EMEA for Vidaza in the treatment of patients with higher-risk myelodysplastic syndromes. If successful, it will become the first drug to be approved in the EU for MDS. However, Pharmion will need to establish a strong market position in the EU market in order to minimize the impact of future competition.
Published By Datamonitor
|
16 Jan 2008 |
|
CommentWire
|
The impressive results reported for previously untreated multiple myeloma patients make Velcade likely to receive approval in the US as a first-line therapy. In this setting, the drug could experience considerable uptake due to its proven activity and favorable safety profile.
Published By Datamonitor
|
16 Jun 2008 |
|
Expert View
|
Biovest, a subsidiary of Accentia, has announced positive data from a pivotal trial of BiovaxID in lymphoma, and the vaccine now stands a good chance of becoming the first therapeutic cancer vaccine to gain approval in the seven major markets. However, despite this breakthrough, a number of economical and logistical issues could prevent the vaccine from achieving significant market penetration.
Published By Datamonitor
|
18 Jul 2008 |
|
CommentWire
|
Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients. Velcade would see considerable uptake if the drug is approved in the first-line setting, due to its proven activity and favorable safety profile compared to current treatment regimens.
Published By Datamonitor
|
28 Jul 2008 |
|
CommentWire
|
The EMEA has granted Velcade approval for use in the first-line treatment setting for multiple myeloma. With this line extension, Velcade will be available across all lines of multiple myeloma therapy, realizing its full commercial potential and offering a new treatment option to patients ineligible for bone marrow transplantation.
Published By Datamonitor
|
09 Sep 2008 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.